Device-guided Breathing Exercises on Blood Pressure in Diabetic Patients (Reperate3)
|ClinicalTrials.gov Identifier: NCT00951119|
Recruitment Status : Completed
First Posted : August 4, 2009
Last Update Posted : October 24, 2012
Rationale: Hypertension is an important risk factor of cardiovascular disease, especially in patients with type 2 diabetes mellitus (T2DM). A relatively recent development for the treatment of hypertension is the use of breathing exercises. The investigators' previous studies with a breathing device did not show any positive results. However, these studies and other trials investigating the effects of breathing devices had not a double-blind design. Therefore, the investigators want to perform a randomized, double-blind, controlled trial in a population of T2DM patients.
Objective: To determine the effect of a device slowing breathing (Resperate©) on office systolic blood pressure (SBP) in diabetic patients with treated hypertension with moderate BP control.
Study design: A randomized, double-blind, controlled trial.
Study population: Patients with type 2 diabetes mellitus, over 18 years old and a baseline systolic blood pressure between 140-160 mm Hg.
Intervention: One group receives treatment with a breathing device (Resperate©) and the other group receives treatment with a "control" breathing device. The latter device does not try to alter the breathing pattern.
Main study parameters/endpoints: The effect of the breathing device on SBP is the main study parameter. Secondary endpoints include diastolic blood pressure (DBP) and quality of life.
|Condition or disease||Intervention/treatment||Phase|
|Hypertension in Type 2 Diabetes||Device: Resperate||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||48 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||The Effect of Device-guided Breathing Exercises on Blood Pressure in Diabetic Patients With Hypertension (Resperate-3) A Randomized, Double-blind Controlled Trial|
|Study Start Date :||September 2009|
|Actual Primary Completion Date :||May 2012|
|Actual Study Completion Date :||June 2012|
Experimental: resperate device
Resperate© is a device that helps to slow down breathing. This device can measure the breathing patterns through a breathing sensor mounted on the upper abdomen or chest. Furthermore, music-like sound patterns can be composed similar to this breathing pattern, which the patient can hear through the headphones of the Resperate©. By prolonging the expiration, which can be voluntarily used by the user, the frequency of respiration can be slowed down and become more stable (aim"<10 breathings per minute).
device-guided breathing exercises
Sham Comparator: control device
Resperate device without slowing of breathing
breathing device without slowing of breathing frequency
- The effect of the breathing device on SBP is the main study parameter [ Time Frame: 8 weeks ]
- Secondary endpoints include diastolic blood pressure (DBP) and quality of life. [ Time Frame: 8 weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00951119
|Isala Clinics, Diabetes Centre|
|Zwolle, Netherlands, 8000 GM|
|Zwolle, Netherlands, 8000 GM|
|Study Director:||HEnk J.G. Bilo, MD, PhD, Professor, FRCP||Diabetes centre, isala clinics|